Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Hepatocellular carcinoma (HCC) is on the rise worldwide, and its incidence in diabetic patients is two to three times that of non-diabetics. Current therapeutic options fail to provide considerable survival benefits to patients with HCC. There is a strong possibility that the FDA-approved antidiabet...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Amir Mohamed Abdelhamid, Sameh Saber, Mahmoud E. Youssef, Ahmed Gaafar Ahmed Gaafar, Hanan Eissa, Marwa A. Abd-Eldayem, Mohammed Alqarni, Gaber El-Saber Batiha, Ahmad J. Obaidullah, Mohamed Awad Shahien, Eman El-Ahwany, Noha A. Amin, Mohamed Ali Etman, Mohamed M.Y. Kaddah, Eslam E. Abd El-Fattah
Format:	article
Langue:	EN
Publié:	Elsevier 2022
Sujets:	Hepatocellular carcinoma Emagliflozin/metformin Autophagy Apoptosis Angiogenesis Metastasis Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/243e31ff9d064d9ab4bb5a9d133137d8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Documents similaires